Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing

Kevin C. Hart(Stanford University), Maya F. Kotturi(Alameda Hospital), Paul R. Hinton(IGM Biosciences (United States)), Mandy Li(IGM Biosciences (United States)), Kathryn Logronio(IGM Biosciences (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Marigold Manlusoc(IGM Biosciences (United States)), Maya K. Leabman(IGM Biosciences (United States)), Dean Ng(IGM Biosciences (United States)), Keyu Li(Sichuan University), Poonam Yakkundi(IGM Biosciences (United States)), Bruce A. Keyt, Genevive Hernandez(Sutro Biopharma (United States)), Angus M. Sinclair(LabGenius (United Kingdom)), Thomas Manley(IGM Biosciences (United States))
Cancer Research
June 15, 2022
Cited by 1


Related Papers